AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals has achieved an important step toward completion, having cleared US Federal Trade Commission review. 16 April 2021
Swiss firm Urovant Sciences, a wholly-owned subsidiary of Sumitomo Dainippon Pharma, has launched Gemtesa (vibegron) for the treatment of overactive bladder (OAB) in the USA. 13 April 2021
The partnership of Porto, Portugal-based FairJourney Biologics and Cambridge, UK-based Iontas have teamed up with Belgo-Dutch immunology company argenx in a new collaboration. 12 April 2021
French vaccines specialist Sanofi is to invest 400 million euros ($476 million) over five years in the creation of a manufacturing facility in Singapore. 12 April 2021
Pfizer and BioNTech yesterday requested amendments to the US Emergency Use Authorization (EUA) of their vaccine (BNT162b2/Comirnaty) to expand the use in adolescents 12 to 15 years of age from the US Food and Drug Administration. 10 April 2021
Japanese drugmaker Mitsubishi Tanabe Pharma has out-licensed the aldosterone synthase inhibitor MT-4129 to privately-held US company Mineralys Therapeutics. 8 April 2021
The European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of US biotech firm Biogen’s Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis (MS). 7 April 2021
Oxford Biomedica has signed a new three year deal with Germany’s Boehringer Ingelheim to manufacture and supply various types of viral vectors. 6 April 2021
The USA has put Johnson & Johnson in charge of a plant that ruined 15 million doses of its COVID-19 vaccine and has stopped AstraZeneca from using the facility, a senior health official said on Saturday, according to a report by Express Pharma. 4 April 2021
Kite, a Gilead Sciences subsidiary, has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 2 April 2021
Enthera Pharmaceuticals, a biotech company developing novel disease-modifying biologics that re-establish stem cell capabilities to treat specific autoimmune diseases, today announced the appointment of Claudia Nardini as vice president of research and development to support the company’s manufacturing and regulatory divisions. 1 April 2021
Germany’s Merck KGaA has exercised an option to develop an additional bispecific program under an ongoing collaboration with UK-based F-star Therapeutics. 1 April 2021
Rare disease specialist Amryt Pharma has submitted a New Drug Application (NDA) to the US regulator for Oleogel-S10, to treat junctional and dystrophic epidermolysis bullosa (EB). 31 March 2021
CureVac has announced a partnership with fellow Germany-headquartered Celonic Group for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV. 30 March 2021
New Jersey, USA-based Rocket Pharmaceuticals has picked up European Priority Medicines (PRIME) designation for its investigational gene therapy RP-L201. 30 March 2021
The US Food and Drug Administration (FDA) has approved two supplements to Biological License Applications from human protein manufacturer Octapharma, strengthening the family-owned company’s pediatric critical care product portfolio. 29 March 2021
UK biotech Albumedix has entered into a distribution agreement with recognized reagent supplier FUJIFILM Wako Pure Chemical in Japan and China including Hong Kong. 29 March 2021
Gilead Sciences said on Friday that Flavius Martin will join the company as executive vice president, research, and will become a member of the company’s senior leadership team, reporting to chairman and chief executive Daniel O’Day. 27 March 2021
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024